Pharmaceuticals

The pharmaceutical industry has been for decades one of the most profitable worldwide. Serious challenges, such as the expiry of long-term lucrative patents (Lipitor, to mention just one) and the cuts in healthcare and R&D in many countries worldwide, can pose a challenge to the growth of the industry. Which drug can save the life of the pharmaceutical industry? Highly differentiated strategies: this is what companies should focus on now if they want to stay competitive. Do you want to know more?

You can get a detailed picture of the market and refine your marketing, brand, and sales strategies with the reliable, up-to-date business information provided by the extensive range of reports, books and subscriptions listed under Research and Markets’ Pharmaceuticals category. They cover markets, companies (big Pharma, mid-sized specialty pharmaceutical companies, generic manufacturers, and small firms), technologies, e-healthcare, pharmaeconomics, drug discovery, and drug delivery.

The product coverage is huge. It includes OTC drugs as well disorder and goal-specific products related to respiration, oncology, vitamins, cardio, analgesics, central nervous system, generics, immune disorders, and women’s health. Show Less ... more

• Psoriasis - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 107
  Psoriasis - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Psoriasis Pipeline Review, Q4 2010”, provides an overview of the Psoriasis therapeutic pipeline. This report provides information...

• Acute Ischemic Stroke - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 59
  Acute Ischemic Stroke - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Acute Ischemic Stroke Pipeline Review, Q4 2010”, provides an overview of the Acute Ischemic Stroke therapeutic pipeline....

• Peripheral Arterial Disease - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 60
  Peripheral Arterial Disease - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Peripheral Arterial Disease Pipeline Review, Q4 2010”, provides an overview of the Peripheral Arterial Disease...

• Acute Myelocytic Leukemia (AML) - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 372
  Acute Myelocytic Leukemia (AML) - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Acute Myelocytic Leukemia Pipeline Review, Q4 2010”, provides an overview of the Acute Myelocytic Leukemia...

• Hepatitis C - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 155
  Hepatitis C - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Hepatitis C Pipeline Review, Q4 2010”, provides an overview of the Hepatitis C therapeutic pipeline. This report provides information...

• Dyslipidemia - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 87
  Dyslipidemia - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Dyslipidemia Pipeline Review, Q4 2010”, provides an overview of the Dyslipidemia therapeutic pipeline. This report provides...

• Bipolar Depression - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 80
  Bipolar Depression - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Bipolar Depression Pipeline Review, Q4 2010”, provides an overview of the Bipolar Depression therapeutic pipeline. This...

• Thrombocytopenia - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 50
  Thrombocytopenia - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Thrombocytopenia Pipeline Review, Q4 2010”, provides an overview of the Thrombocytopenia therapeutic pipeline. This report...

• Meningitis - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 42
  Meningitis - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Meningitis Pipeline Review, Q4 2010”, provides an overview of the Meningitis therapeutic pipeline. This report provides information...

• Hormone Replacement Therapy - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 25
  Hormone Replacement Therapy - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Hormone Replacement Therapy Pipeline Review, Q4 2010”, provides an overview of the Hormone Replacement Therapy...

• Dysmenorrhea - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 28
  Dysmenorrhea - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Dysmenorrhea Pipeline Review, Q4 2010”, provides an overview of the Dysmenorrhea therapeutic pipeline. This report provides...

• Non-Small Cell Lung Cancer - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 495
  Non-Small Cell Lung Cancer - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Non-Small Cell Lung Cancer Pipeline Review, Q4 2010”, provides an overview of the Non-Small Cell Lung Cancer...

• Leishmaniasis (Kala-Azar) - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 52
  Leishmaniasis (Kala-Azar) - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Leishmaniasis (Kala-Azar) Pipeline Review, Q4 2010”, provides an overview of the Leishmaniasis (Kala-Azar) therapeutic...

• Celiac Disease - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 36
  Celiac Disease - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Celiac Disease Pipeline Review, Q4 2010”, provides an overview of the Celiac Disease therapeutic pipeline. This report provides...

• Polycythemia Vera - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 30
  Polycythemia Vera - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Polycythemia Vera Pipeline Review, Q4 2010”, provides an overview of the Polycythemia Vera therapeutic pipeline. This...

• Macular Degeneration - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 49
  Macular Degeneration - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Macular Degeneration Pipeline Review, Q4 2010”, provides an overview of the Macular Degeneration therapeutic pipeline....

• Lupus Nephritis - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 42
  Lupus Nephritis - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Lupus Nephritis Pipeline Review, Q4 2010”, provides an overview of the Lupus Nephritis therapeutic pipeline. This report...

• Cachexia - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 44
  Cachexia - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Cachexia Pipeline Review, Q4 2010”, provides an overview of the Cachexia therapeutic pipeline. This report provides information...

• Spasticity - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 42
  Spasticity - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Spasticity Pipeline Review, Q4 2010”, provides an overview of the Spasticity therapeutic pipeline. This report provides information...

• Male Hypogonadism - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 45
  Male Hypogonadism - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Male Hypogonadism Pipeline Review, Q4 2010”, provides an overview of the Male Hypogonadism therapeutic pipeline. This...

• Genital Herpes - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 41
  Genital Herpes - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Genital Herpes Pipeline Review, Q4 2010”, provides an overview of the Genital Herpes therapeutic pipeline. This report provides...

• Autism - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 55
  Autism - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Autism Pipeline Review, Q4 2010”, provides an overview of the Autism therapeutic pipeline. This report provides information on the...

• Osteoarthritis Pain - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 50
  Osteoarthritis Pain - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Osteoarthritis Pain Pipeline Review, Q4 2010”, provides an overview of the Osteoarthritis Pain therapeutic pipeline....

• Growth Disorders - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 44
  Growth Disorders - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Growth Disorders Pipeline Review, Q4 2010”, provides an overview of the Growth Disorders therapeutic pipeline. This report...

• Acute Heart Failure - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 31
  Acute Heart Failure - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Acute Heart Failure Pipeline Review, Q4 2010”, provides an overview of the Acute Heart Failure therapeutic pipeline....

• Von Willebrand Disease - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 34
  Von Willebrand Disease - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Von Willebrand Disease Pipeline Review, Q4 2010”, provides an overview of the Von Willebrand Disease therapeutic...

• Hepatitis A - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 31
  Hepatitis A - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Hepatitis A Infection Pipeline Review, Q4 2010”, provides an overview of the Hepatitis A Infection therapeutic pipeline. This...

• Fatty Liver Disease - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 38
  Fatty Liver Disease - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Fatty Liver Disease Pipeline Review, Q4 2010”, provides an overview of the Fatty Liver Disease therapeutic pipeline....

• Hyperparathyroidism - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 37
  Hyperparathyroidism - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Hyperparathyroidism Pipeline Review, Q4 2010”, provides an overview of the Hyperparathyroidism therapeutic pipeline....

• Ascites - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 28
  Ascites - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Ascites Pipeline Review, Q4 2010”, provides an overview of the Ascites therapeutic pipeline. This report provides information on...

• Aspergillosis - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 36
  Aspergillosis - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Aspergillosis Pipeline Review, Q4 2010”, provides an overview of the Aspergillosis therapeutic pipeline. This report provides...

• Allergic Conjunctivitis - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 48
  Allergic Conjunctivitis - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Allergic Conjunctivitis Pipeline Review, Q4 2010”, provides an overview of the Allergic Conjunctivitis therapeutic...

• Onychomycosis - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 51
  Onychomycosis - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Onychomycosis Pipeline Review, Q4 2010”, provides an overview of the Onychomycosis therapeutic pipeline. This report provides...

• Urinary Tract Infections - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 38
  Urinary Tract Infections - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Urinary Tract Infections Pipeline Review, Q4 2010”, provides an overview of the Urinary Tract Infections therapeutic...

• Influenza A - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 39
  Influenza A - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Influenza A Infection Pipeline Review, Q4 2010”, provides an overview of the Influenza A Infection therapeutic pipeline. This...

• Ulcerative Colitis - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 79
  Ulcerative Colitis - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Ulcerative Colitis Pipeline Review, Q4 2010”, provides an overview of the Ulcerative Colitis therapeutic pipeline. This...

• Gastroesophageal Reflux Disease - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 51
  Gastroesophageal Reflux Disease - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Gastroesophageal reflux disease (GERD) Pipeline Review, Q4 2010”, provides an overview of the Gastroesophageal...

• Pouchitis - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 20
  Pouchitis - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Pouchitis Pipeline Review, Q4 2010”, provides an overview of the Pouchitis therapeutic pipeline. This report provides information...

• Friedrich Ataxia - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 33
  Friedrich Ataxia - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Friedrich Ataxia Pipeline Review, Q4 2010”, provides an overview of the Friedrich Ataxia therapeutic pipeline. This report...

• Polycystic Kidney Disease - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 37
  Polycystic Kidney Disease - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Polycystic Kidney Disease Pipeline Review, Q4 2010”, provides an overview of the Polycystic Kidney Disease therapeutic...

• Tuberculosis - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 89
  Tuberculosis - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Tuberculosis Pipeline Review, Q4 2010”, provides an overview of the Tuberculosis therapeutic pipeline. This report provides...

• Crohns Disease - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 88
  Crohns Disease - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Crohns Disease Pipeline Review, Q4 2010”, provides an overview of the Crohns Disease therapeutic pipeline. This report provides...

• Alopecia - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 31
  Alopecia - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Alopecia Pipeline Review, Q4 2010”, provides an overview of the Alopecia therapeutic pipeline. This report provides information...

• Familial Hypercholesterolemia - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 48
  Familial Hypercholesterolemia - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Familial Hypercholesterolemia Pipeline Review, Q4 2010”, provides an overview of the Familial Hypercholesterolemia...

• Pipeline Insight: Insulin Antidiabetics - Novel analogs show promise as alternative delivery methods prove less attractive.

  EURO€ 8,763.00USD$ 11,400.00GBP£ 7,372.00AUD$ 11,150.00JPY¥ 1,125,556.00SEK 74 851,00CHF 10'745.00CAD$ 11,616.00 Datamonitor, Dec 2010 , Pages: 177
  Introduction The insulin antidiabetics market is forecast to grow from 10.6 billion in 2009 to $16.4 billion in 2019 for the seven major markets, with pipeline products contributing 18% of sales. Basal...

• Macular Edema - Drug Pipeline Analysis and Market Forecasts to 2016

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 GlobalData, Dec 2010 , Pages: 39
  “Macular Edema Therapeutics - Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global macular edema therapeutics market The report identifies...

• Cystic Fibrosis - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 81
  Cystic Fibrosis - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Cystic Fibrosis Pipeline Review, Q4 2010”, provides an overview of the Cystic Fibrosis therapeutic pipeline. This report...

• Dengue - Pipeline Review, Q4 2010

  EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00 Global Markets Direct, Dec 2010 , Pages: 41
  Dengue - Pipeline Review, Q4 2010 Summary Global Markets Direct’s, “Dengue Pipeline Review, Q4 2010”, provides an overview of the Dengue therapeutic pipeline. This report provides information on the...

• China Chemical Pharmaceutical Industry Report, 2009-2010

  EURO€ 1,691.00USD$ 2,200.00GBP£ 1,423.00AUD$ 2,152.00JPY¥ 217,213.00SEK 14 445,00CHF 2'074.00CAD$ 2,242.00 Research In China, Dec 2010 , Pages: 52
  China’s chemical pharmaceutical industry has maintained a good momentum of growth in recent years In 2009, the number of chemical pharmaceutical manufacturers reached 2,434, up 7 5% year-on-year; the...

• China Chemical Pharmaceutical Industry Report, 2009-2010

  EURO€ 1,691.00USD$ 2,200.00GBP£ 1,423.00AUD$ 2,152.00JPY¥ 217,213.00SEK 14 445,00CHF 2'074.00CAD$ 2,242.00 Research In China, Dec 2010 , Pages: 52
  China’s chemical pharmaceutical industry has maintained a good momentum of growth in recent years In 2009, the number of chemical pharmaceutical manufacturers reached 2,434, up 7 5% year-on-year; the...